Login
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc

syndax.com

What Do They Do?

Sells Revuforj for acute leukemia and Niktimvo for chronic graft-versus-host disease to specialty distributors and pharmacies, while developing additional cancer medicines.

How Do They Make Money?

Specialty distributors and pharmacies buy Revuforj; sales are counted when the product is delivered, and payment terms are no longer than one year. Syndax also receives its share of Niktimvo profits as sales and related costs occur, plus license payments, milestones and royalties tied to contract events or sales.

revenue
SegmentShareRevenue
Net product revenue
Sold outright

72%
Collaboration revenue
25%
Milestone revenue
Licensed
3.0%

Who Are Their Customers?

Specialty distributors and specialty pharmacies buy Revuforj from Syndax and resell it to healthcare providers, patients and other pharmacies. Syndax handles Revuforj sales through its own team and third parties, co-commercializes Niktimvo with Incyte, and works with Incyte on axatilimab commercialization globally.

Do Revenues Turn Into Profits?

No. It lost $285.4M in FY2025.

Operating income, FY2025
−158% of revenue
▲ +20% (Loss) vs FY2024 (−$339.7M, −1434%)
Net income, FY2025
−166% of revenue
▲ +10% (Loss) vs FY2024 (−$318.8M, −1346%)
Free cash flow, FY2025
−188% of revenue
▼ −18% (Loss) vs FY2024 (−$274.9M, −1161%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +82%
vs $45.9M in Q3 FY2025
Net income
▲ +19% (Loss)
vs −$60.7M in Q3 FY2025

Growing. Revenue grew 23% in 4 years, from $139.7M in FY2021 to $172.4M in FY2025, about 5% a year.

From development to commercial sales The older report described revumenib and axatilimab as clinical-stage candidates; the latest describes Revuforj and Niktimvo as approved medicines and reports their commercial launches.

Revenue over time
Net product revenue Collaboration revenue Milestone revenue
$200M$100M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support